Shares in Amgen were down nearly 7% after close of trading yesterday after the company’s heart failure drug omecamtiv mecarbil disappointed in a large phase 3 trial.

and evidence of atherosclerotic cardiovascular disease (ASCVD). The main objective of the study was to show a durability of response, which has been achieved, allowing Amgen to press ahead with ...

It primarily focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas. Read More on AMGN: Amgen NewsMORE Related Stocks Indices Commodities ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

At the heart of the dispute is whether Amgen's claims are ... court's view that companies that prove the commercial viability of products should not be penalized by small and inconclusive clinical ...